Full Press Release Details
Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full
Recovery from Erectile Dysfunction After
may provide benefits for patients who cannot take or do not respond to erectile dysfunction drugs currently on the market
TIKVA, Israel, April 11, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline
of proprietary small molecule drugs that address inflammatory diseases, cancer, and sexual dysfunction, today reported new findings
for its drug candidate, CF602, showing statistically significant full recovery from erectile dysfunction after one single dose
treatment in a pre-clinical diabetic model. Can-Fite plans to file an Investigational New Drug (IND) application with the U.S.
Food and Drug Administration (FDA) for CF602 in the fourth quarter of 2016 and plans to initiate a Phase I trial following IND
a recent study, CF602 induced a dose-dependent, linear effect in a diabetic mellitus rat model after treatment with one single
dose of CF602. One hour after dosing, sexual function was measured. Statistically significant full recovery from erectile dysfunction
took place in rats treated with a 500 /kg dose.
is a significant segment of the erectile dysfunction market that is not addressed by PDE5 inhibitors, the class of drugs that
are widely used in the market today. Due to CF602's novel mechanism of action, it may provide benefits for patients who
do not respond to PDE5 inhibitors, or cannot take PDE5 inhibitors due to contraindications.
latest findings for CF602 are very encouraging and they add to the growing body of data that forms the basis of our planned IND
submission to the FDA," stated Can-Fite CEO Dr. Pnina Fishman.
Can-Fite BioPharma Ltd.
BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology
that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction.
The Company's CF101 drug candidate is scheduled to enter Phase III trials in 2016 for two indications, rheumatoid arthritis and
psoriasis. Can-Fite's liver cancer drug CF102 is in Phase II trials for patients with liver cancer and is slated to enter
Phase II for the treatment of non-alcoholic steatohepatitis (NASH). CF102 has been granted Orphan Drug Designation in the U.S.
and Europe and Fast Track Designation as a second line treatment for hepatocellular carcinoma by the U.S. Food and Drug Administration.
CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's
third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and is being prepared
for an IND submission to the FDA and a Phase I trial. These drugs have an excellent safety profile with experience in over
1,000 patients in clinical studies to date. For more information please visit: www.can-fite.com.
press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other
things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition,
from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words such as "believe," "expect," "intend,"
"plan," "may," "should" or "anticipate" or their negatives or other variations of these
words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters.
These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities
and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive
officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject
to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or
implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially
from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized
in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry
sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control.
Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information,
future events or otherwise.